Search SAMHSA Publications and Digital Products
Store Facets Summary
- Clear all filters
- Remove Professional Care Providers
- Remove Public Health Professionals
- Remove People with Substance Use or Abuse Problems as Audience
- Remove People with Substance Use or Abuse Problems as Population Group
- Remove Buprenorphine
- Remove Cocaine
- Remove Methadone
- Remove Pain Relievers
- Remove Naltrexone
- Remove Cognitive Behavioral Therapy
- Remove Motivational Interventions
- Remove Treatment Planning
Main page content
Published: December 2021This resource provides information to primary care providers and practices on how to implement opioid use disorder treatment using buprenorphine. It identifies common barriers and strategies to overcome them. It documents step-by-step tactics to support buprenorphine implementation.
Published: October 2021This updated TIP reviews what is known about treating the medical, psychiatric, and SUD-related problems associated with the use of cocaine and methamphetamine, as well as the misuse of prescription stimulants. The TIP offers recommendations on treatment approaches and maximizing treatment engagement and retention, and strategies for initiating and maintaining abstinence.
Published: August 2021The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
Published: July 2021This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.